164 related articles for article (PubMed ID: 8355145)
1. [Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].
Hirayama F
Yakugaku Zasshi; 1993 Jun; 113(6):425-37. PubMed ID: 8355145
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaceutical application of cyclodextrins as multi-functional drug carriers].
Uekama K
Yakugaku Zasshi; 2004 Dec; 124(12):909-35. PubMed ID: 15577263
[TBL] [Abstract][Full Text] [Related]
3. Peracylated beta-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine.
Uekama K; Horikawa T; Yamanaka M; Hirayama F
J Pharm Pharmacol; 1994 Sep; 46(9):714-7. PubMed ID: 7837039
[TBL] [Abstract][Full Text] [Related]
4. [Novel approach of cyclodextrin-based pharmaceutical formulation].
Uekama K
Yakugaku Zasshi; 2012; 132(1):85-105. PubMed ID: 22214584
[TBL] [Abstract][Full Text] [Related]
5. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.
Arima H; Kondo T; Irie T; Uekama K
J Pharm Sci; 1992 Nov; 81(11):1119-25. PubMed ID: 1447717
[TBL] [Abstract][Full Text] [Related]
6. Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins.
Tanino T; Ogiso T; Iwaki M; Yamaguchi T; Kakehi K
Biol Pharm Bull; 1999 Oct; 22(10):1099-105. PubMed ID: 10549863
[TBL] [Abstract][Full Text] [Related]
7. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
8. Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives.
Ikeda Y; Kimura K; Hirayama F; Arima H; Uekama K
J Control Release; 2000 May; 66(2-3):271-80. PubMed ID: 10742586
[TBL] [Abstract][Full Text] [Related]
9. Slow-release characteristics of diltiazem from ethylated beta-cyclodextrin complexes.
Horiuchi Y; Hirayama F; Uekama K
J Pharm Sci; 1990 Feb; 79(2):128-32. PubMed ID: 2324960
[TBL] [Abstract][Full Text] [Related]
10. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
[TBL] [Abstract][Full Text] [Related]
11. [Use of water-soluble beta-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery].
Arima H; Kondo T; Irie T; Hirayama F; Uekama K; Miyaji T; Inoue Y
Yakugaku Zasshi; 1992 Jan; 112(1):65-72. PubMed ID: 1578346
[TBL] [Abstract][Full Text] [Related]
12. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
Motoyama K; Kameyama K; Onodera R; Araki N; Hirayama F; Uekama K; Arima H
Eur J Pharm Sci; 2009 Oct; 38(3):249-61. PubMed ID: 19664706
[TBL] [Abstract][Full Text] [Related]
13. Design and in-vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose.
Wang Z; Horikawa T; Hirayama F; Uekama K
J Pharm Pharmacol; 1993 Nov; 45(11):942-6. PubMed ID: 7908033
[TBL] [Abstract][Full Text] [Related]
14. Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin:cellulose derivative combination as a modified-release drug carrier.
Uekama K; Matsubara K; Abe K; Horiuchi Y; Hirayama F; Suzuki N
J Pharm Sci; 1990 Mar; 79(3):244-8. PubMed ID: 2338635
[TBL] [Abstract][Full Text] [Related]
15. Preparation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin and its nuclear magnetic resonance spectroscopic characterization.
Hirayama F; Kurihara M; Horiuchi Y; Utsuki T; Uekama K; Yamasaki M
Pharm Res; 1993 Feb; 10(2):208-13. PubMed ID: 8384365
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of cyclodextrin-based drug formulation.
Uekama K
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):900-15. PubMed ID: 15304981
[TBL] [Abstract][Full Text] [Related]
17. Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits.
Fernandes CM; Ramos P; Falcão AC; Veiga FJ
J Control Release; 2003 Feb; 88(1):127-34. PubMed ID: 12586510
[TBL] [Abstract][Full Text] [Related]
18. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.
Yoshida A; Yamamoto M; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1989 Apr; 37(4):1059-63. PubMed ID: 2766408
[TBL] [Abstract][Full Text] [Related]
19. Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
Hirayama F; Mieda S; Miyamoto Y; Arima H; Uekama K
J Pharm Sci; 1999 Oct; 88(10):970-5. PubMed ID: 10514341
[TBL] [Abstract][Full Text] [Related]
20. Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats.
Kamada M; Hirayama F; Udo K; Yano H; Arima H; Uekama K
J Control Release; 2002 Aug; 82(2-3):407-16. PubMed ID: 12175753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
